Cancer News Roundup: Stroke Risk, 9/11 Deaths, and New Drug Pricing
A large study found that cancer patients face an increased risk of ischemic stroke, especially in the months after diagnosis, with lung and pancreatic cancers showing the strongest association. On the 25th anniversary of 9/11, cancer deaths linked to the attacks have surpassed the number of immediate victims. Additionally, a new pancreatic cancer drug has set a record for cost, raising access concerns.
The retrospective cohort study identified a significantly elevated risk of ischemic stroke among cancer patients, particularly within the first few months following diagnosis. Lung and pancreatic cancers demonstrated the strongest association, suggesting that these aggressive malignancies may trigger prothrombotic states or that treatment-related factors contribute to early cerebrovascular events.
The pancreatic cancer drug daraxonrasib has achieved a new standard of care but also set a record for oncology drug pricing, raising concerns about affordability. Its expanded access program has closed, leaving some eligible patients without coverage. Meanwhile, cancer deaths linked to the 9/11 attacks now exceed the immediate death toll, highlighting the long-term health consequences of environmental exposures.
These findings could prompt earlier cardiovascular screening and prophylactic measures in newly diagnosed cancer patients, potentially improving survival but also adding to treatment burden. The record cost of daraxonrasib may exacerbate existing disparities in cancer care, as patients with limited insurance or financial resources could face delayed or forgone treatment. The 9/11 cancer death milestone underscores the prolonged health impact of disasters, possibly influencing future emergency preparedness and long-term health monitoring policies. These developments may shape clinical guidelines, drug pricing negotiations, and public health funding priorities.